These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 3688242)

  • 1. Role of AVP in malignant DOC-salt hypertension: studies using vascular and antidiuretic antagonists.
    Filep J; Frölich JC; Földes-Filep E
    Am J Physiol; 1987 Nov; 253(5 Pt 2):F952-8. PubMed ID: 3688242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence against a vasopressor role of ADH in malignant DOC-salt hypertension.
    Filep J; Frölich JC; Fejes-Toth G
    Clin Exp Hypertens A; 1985; 7(10):1457-70. PubMed ID: 3841034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of vasopressin to the maintenance of blood pressure in deoxycorticosterone-salt induced malignant hypertension in spontaneously hypertensive rats.
    Hiwatari M; Abrahams JM; Saito T; Johnston CI
    Clin Sci (Lond); 1986 Feb; 70(2):191-8. PubMed ID: 3956109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of high sodium renal hypertension during chronic blockade of the vascular effects of vasopressin.
    Hinojosa C; Haywood JR
    J Pharmacol Exp Ther; 1986 Aug; 238(2):492-6. PubMed ID: 2874211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The significance of vasopressin as a pressor agent.
    Hofbauer KG; Studer W; Mah SC; Michel JB; Wood JM; Stalder R
    J Cardiovasc Pharmacol; 1984; 6 Suppl 2():S429-38. PubMed ID: 6206352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Further in vivo evidence for antagonist-to-antidiuretic action of arginine vasopressin.
    Ishikawa S; Kim JK; Schrier RW
    Am J Physiol; 1983 Nov; 245(5 Pt 1):R713-9. PubMed ID: 6688929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pressor response to vasopressin and impaired baroreflex function in DOC-salt hypertension.
    Matsuguchi H; Schmid PG
    Am J Physiol; 1982 Jan; 242(1):H44-9. PubMed ID: 7058912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and some pharmacological properties of 18 potent O-alkyltyrosine-substituted antagonists of the vasopressor responses to arginine-vasopressin.
    Manning M; Lammek B; Bankowski K; Seto J; Sawyer WH
    J Med Chem; 1985 Oct; 28(10):1485-91. PubMed ID: 4045923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contributions of vasopressin and other pressor systems to DOC-salt hypertension in rats.
    Mento PF; Wang HH; Sawyer WH
    Proc Soc Exp Biol Med; 1984 Jan; 175(1):58-63. PubMed ID: 6694969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does vasopressin sustain blood pressure in conscious spontaneously hypertensive rats?
    Filep J; Fejes-Tóth G
    Hypertension; 1986 Jun; 8(6):514-9. PubMed ID: 2872162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthetic antagonists of in vivo antidiuretic and vasopressor responses to arginine-vasopressin.
    Manning M; Lammek B; Kolodziejczyk AM; Seto J; Sawyer WH
    J Med Chem; 1981 Jun; 24(6):701-6. PubMed ID: 7252979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pressor response to vasopressin and norepinephrine in DOC-salt hypertensive and prehypertensive rats.
    Ouchi Y; Yazaki Y; Tsai RC; Ashida T
    Tohoku J Exp Med; 1988 Feb; 154(2):125-33. PubMed ID: 3381222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Central mechanisms in DOC-salt hypertensive rats.
    Matsuguchi H; Sharabi FM; O'Connor G; Mark AL; Schmid PG
    Clin Exp Hypertens A; 1982; 4(8):1303-21. PubMed ID: 7116668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does vasopressin contribute to salt-induced hypertension in the Dahl strain?
    Matsuguchi H; Schmid PG; Van Orden D; Mark AL
    Hypertension; 1981; 3(2):174-81. PubMed ID: 7216372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasopressin and sympathetic nervous functions both contribute to development and maintenance of hypertension in DOCA-salt rats.
    Takata Y; Yamashita Y; Takishita S; Fujishima M
    Clin Exp Hypertens A; 1988; 10(2):203-27. PubMed ID: 3370846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for independent actions of vasopressin on renal inner medullary cyclic AMP and prostaglandin E production: relationship of the prostaglandin E response to hormone pressor activity.
    Campbell HT; Craven PA; DeRubertis FR
    Metabolism; 1982 Oct; 31(10):1035-41. PubMed ID: 6290836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of endothelin and vasopressin in DOCA-salt hypertension.
    Yu M; Gopalakrishnan V; McNeill JR
    Br J Pharmacol; 2001 Apr; 132(7):1447-54. PubMed ID: 11264238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of vascular and tubular effects of arginine-vasopressin to the development of deoxycorticosterone acetate (DOCA)-salt hypertension in rats.
    Hofbauer KG; Mah SC; Wood JM; Baum HP; Hänni H; Opperman JR; Kraetz J
    J Hypertens Suppl; 1984 Dec; 2(3):S333-5. PubMed ID: 6599676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocrine control of salt and water excretion: the role of vasopressin in DOCA-salt hypertension.
    Hofbauer KG; Mah SC; Baum HP; Hänni H; Wood JM; Kraetz J
    J Cardiovasc Pharmacol; 1984; 6 Suppl 1():S184-91. PubMed ID: 6204139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular effects of arginine vasopressin during fluid deprivation in the rat.
    Aisenbrey GA; Handelman WA; Arnold P; Manning M; Schrier RW
    J Clin Invest; 1981 Apr; 67(4):961-8. PubMed ID: 7204578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.